Phase II/III pivotal study of Cannabidiol in Fragile-X-syndrome.

Trial Profile

Phase II/III pivotal study of Cannabidiol in Fragile-X-syndrome.

Phase of Trial: Phase II/III

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Fragile X syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Zynerba Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2018 According to a Zynerba Pharmaceuticals media release, this trial will support a New Drug Application (NDA) for ZYN002 in Fragile-X-syndrome.
    • 09 Jan 2018 New trial record
    • 03 Jan 2018 According to the Zynerba Pharmaceuticals media release, data read out from this study is expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top